Correlation of clinical parameters with risk groups in the test cohort (n = 181)
Characteristic . | Low risk, % . | High risk, % . | P . |
---|---|---|---|
Age, 65 y or older | 30 | 23 | .692 |
Albumin, less than 35 g/L | 17 | 32 | .163 |
β2-microglobulin | |||
Less than 297.5 nM | 57 | 32 | .005 |
297.5 nM to less than 467.5 nM | 23 | 18 | |
467.5 nM or more | 19 | 50 | |
C-reactive protein, 4 mg/L or above | 44 | 59 | .271 |
LDH, 190 IU/L or above | 18 | 59 | < .001 |
Cytogenetic abnormalities | 27 | 77 | < .001 |
GEP-based translocations | |||
CCND1 | 14 | 0 | < .001 |
MMSET | 12 | 23 | |
MAF/MAFB | 7 | 36 | |
No spike | 67 | 41 |
Characteristic . | Low risk, % . | High risk, % . | P . |
---|---|---|---|
Age, 65 y or older | 30 | 23 | .692 |
Albumin, less than 35 g/L | 17 | 32 | .163 |
β2-microglobulin | |||
Less than 297.5 nM | 57 | 32 | .005 |
297.5 nM to less than 467.5 nM | 23 | 18 | |
467.5 nM or more | 19 | 50 | |
C-reactive protein, 4 mg/L or above | 44 | 59 | .271 |
LDH, 190 IU/L or above | 18 | 59 | < .001 |
Cytogenetic abnormalities | 27 | 77 | < .001 |
GEP-based translocations | |||
CCND1 | 14 | 0 | < .001 |
MMSET | 12 | 23 | |
MAF/MAFB | 7 | 36 | |
No spike | 67 | 41 |